RxDoctor Payments Data

Rodney Swillie

Neurology · Birmingham, ALNPI 1013910694

Payments from drug & device makers

$24,572in general payments, 2019–2025

Across 1,544 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Novartis$2K
  • Biogen$1K
  • UCB, Inc.$1K
  • CSL Behring$989
  • Amgen$944
  • plus $15K from 54 others

What the payments were for

  • Speaking & faculty fees$3631%
  • Food & beverage$24,19498%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)277$3,589
Novartis109$1,788
Biogen88$1,141
UCB, Inc.66$1,065
CSL Behring29$989
Amgen(2 entities)54$944
Teva Pharmaceuticals USA, Inc.63$862
AstraZeneca(2 entities)47$819
Acorda Therapeutics, Inc45$809
EMD Serono, Inc.40$799
Lilly USA, LLC48$692
Upsher-smith Laboratories LLC40$667
Lundbeck LLC34$667
SK Life Science, Inc.49$653
Genentech USA, Inc.38$635
Eisai Inc.29$518
Impel Pharmaceuticals Inc.29$511
Neurocrine Biosciences, Inc.31$500
Supernus Pharmaceuticals, Inc.32$473
Amneal Pharmaceuticals LLC31$433
Johnson & Johnson31$400
Acadia Pharmaceuticals Inc28$386
Biohaven Pharmaceuticals, Inc.28$373
Biohaven Pharmaceutical Holding Company Ltd.25$363
Sanofi15$333
Argenx US, Inc.11$268
Pfizer20$267
Avanir Pharmaceuticals, Inc.15$263
Catalyst Pharmaceuticals, Inc.11$203
Neurelis, Inc.14$201
Akcea Therapeutics, Inc.11$198
Sunovion Pharmaceuticals Inc.12$164
Assertio Therapeutics, Inc.11$163
Tanabe Pharma America, Inc.9$152
Bristol Myers Squibb8$150
Kyowa Kirin, Inc.8$139
Ipsen Biopharmaceuticals, Inc6$133
Greenwich Biosciences, Inc.7$130
TG Therapeutics, Inc.8$129
Adamas Pharmaceuticals, Inc.6$128
ANI Pharmaceuticals, Inc.6$124
Sumitomo Pharma America, Inc.6$113
Aquestive Therapeutics, Inc.8$112
Grifols USA, LLC6$110
Takeda Pharmaceuticals U.S.A., Inc.5$108
MDD US Operations, LLC7$107
Otsuka America Pharmaceutical, Inc.5$103
Jazz Pharmaceuticals Inc.4$85
Alnylam Pharmaceuticals Inc.3$75
Avion Pharmaceuticals4$64
Mallinckrodt Hospital Products Inc.3$62
Arbor Pharmaceuticals, Inc.4$57
Boston Scientific3$56
Merz North America, Inc.2$55
Vertical Pharmaceuticals, LLC3$52
Almatica Pharma LLC2$34
Mallinckrodt Enterprises LLC2$31
Averitas Pharma Inc.1$24
Banner Life Sciences, LLC1$18
Currax Pharmaceuticals LLC1$16

How this compares

$24,572 in reported general payments places this provider in the 70th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe13$9,555
DilantinPhenytoin Sodium Extended12$4,041
Levetiracetam81$2,877
Memantine Hcl77$2,560
Oxcarbazepine14$1,633
Pyridostigmine Bromide17$1,093
Selegiline Hcl12$1,050
RizatriptanRizatriptan Benzoate14$817
Phenytoin Sodium Extended24$739
Lacosamide12$682
Zonisamide22$599
Lamotrigine31$587
Divalproex Sodium18$569
Carbidopa-LevodopaCarbidopa/Levodopa19$552
Duloxetine Hcl15$474

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerDilantin$267$4,04112 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$433$1,09317 claims
Upsher-smith Laboratories LLCTopiramate$667$29124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 255 neurology providers in Alabama.

Other neurology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →